Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Korro Bio (KRRO – Research Report), with a price ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative ...

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders ...

Read Our Latest Stock Report on KRRO Korro Bio Trading Up 1.1 % KRRO stock opened at $24.03 on Monday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $41.23 ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...

Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company ...

Korro Bio, Inc. (NASDAQ:KRRO) announced today that Vineet Agarwal has resumed his role as Chief Financial Officer after returning from a medical leave that began on February 11, 2025. The company’s ...